{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 8,
  "pageCount": 53,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "This appears to be a page from a formal government or investigative report.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/8",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "McKinsey failed to disclose its commercial relationships with these opioid manufacturers to FDA.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49c-9c73f606d5da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of contracts: 76",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49c-a0422404cfb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.78,
        "x": 0.11,
        "y": 0.41
      },
      "kind": "paragraph",
      "text": "From 2008 to 2022, McKinsey performed on 76 contracts for the FDA. FDA has paid McKinsey more than $140 million since 2008, including $40 million from CDER, which oversees opioid-related programs. McKinsey provided the Committee with an engagement list for the company's work on 37 FDA matters—fewer than half of the contracts reported in government databases—along with the consultants who worked on those matters. During this period, McKinsey consultants also worked extensively for Purdue. According to an engagement list obtained by the Committee, from 2004 to 2019, McKinsey consulted on at least 75 separate engagements for Purdue and its affiliates. These engagements ranged in duration from several weeks to over a year, and covered subjects ranging from sales",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24ae42cd-98ff-425b-be5e-6e4920c498d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.78,
        "x": 0.11,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "the health care and regulatory practices who worked for FDA and opioid manufacturers at the same time. According to information provided by FDA in response to a request from the Senate and public records requests, McKinsey failed to disclose its commercial relationships with these opioid manufacturers to FDA. The Committee has also obtained evidence that McKinsey shared information that it received through its consulting work for FDA with other McKinsey consultants, and potentially with private sector clients. Documents show that at least one McKinsey consultant encouraged colleagues to share information obtained from their FDA projects with Purdue. Other McKinsey consultants working for both FDA and Purdue appear to have shared FDA proposals within McKinsey, even when senior FDA officials requested that McKinsey limit the distribution of those proposals to certain consultants.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a567c65d-5af7-43f1-8194-175f9bf0c86d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.78,
        "x": 0.11,
        "y": 0.67
      },
      "kind": "source-note",
      "text": "6 McKinsey produced to the Committee staffing information for 37 FDA-McKinsey contracts between 2010 and 2022... 7 Letter from Acting Associate Commissioner Andrew Tantillo... 8 USA Spending... 9 See MCK-HCOR-0355686 to MCK-HCOR-0355698...",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38a85d6f-feb7-43f7-a8f0-37223243a4d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.78,
        "x": 0.11,
        "y": 0.37
      },
      "kind": "title",
      "text": "1. McKinsey Consultants Worked Extensively for Both FDA and Purdue",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e209e7d-541f-4b00-ac5b-cd3ebe5ff00b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of contracts",
      "numberRaw": "76",
      "numberKind": "plain",
      "actionTitle": "McKinsey Consultants Worked Extensively for Both FDA and Purdue",
      "calloutText": "McKinsey failed to disclose its commercial relationships with these opioid manufacturers to FDA.",
      "numberScale": null,
      "numberValue": 76,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5abf7d55-d5e6-487b-bacf-e9bead3b0544",
      "evidence": "From 2008 to 2022, McKinsey performed on 76 contracts for the FDA. FDA has paid McKinsey more than $140 million since 2008, including $40 million from CDER, which oversees opioid-related programs.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}